Does PROBALANâ€™s injectable versus oral formulation change generic substitution risk?

Typically yes. Injectable products may face stricter manufacturing oversight and supply disruption risk, but they are still substitutable with generics where approved equivalents exist.

How quickly do generics enter after PROBALANâ€™s brand-level patent or exclusivity ends?

In vitamin combination categories, entry can be rapid once regulatory and IP barriers are removed, because bioequivalence standards are well established.

What reimbursement strategy most influences PROBALANâ€™s pricing power?

Reference pricing and formulary placement drive whether the brand retains premium net pricing or drops to parity with generics.

What tends to cause PROBALAN revenue volatility even without major competitors?

Supply interruptions, tender resets, and rebate or reimbursement changes that alter ASP and gross-to-net spread.

Is PROBALAN exposed to biosimilar-type competition?

No. As a vitamin-based small-molecule product, it is not a biologic and does not face biosimilar dynamics.

When will the PROBALAN patents expire, and when will generic PROBALAN be available?

Sponsor	Phase
Washington State University	Early Phase 1
National Institutes of Health (NIH)	Early Phase 1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Early Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett	PROBALAN	probenecid	TABLET;ORAL	080966-001	Approved Prior to Jan 1, 1982	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 12, 2026

PROBALAN (Probalamin) market dynamics and financial trajectory: sales, reimbursement, and IP-driven competition outlook

Executive summary

PROBALAN is a branded product in the vitamin B1/B6/B12 family sold in multiple geographies, with market demand driven by neuropathy and “nerve health” prescribing rather than oncology-style utilization. The financial trajectory is shaped by (1) payer preference for low-cost B-complex alternatives, (2) channel sensitivity to local tendering and generic substitution, and (3) the presence or absence of enforceable brand-specific formulation or method patents in the key markets where it is marketed. Competitive pressure typically accelerates after brand-level patent or data exclusivity lapses, with biosimilar dynamics not applicable (non-biologic).

Key business implication: PROBALAN’s revenue resilience depends more on formulary placement and price control outcomes than on complex biologics-type market access. Where multiple B-complex generics exist, the brand’s unit growth tends to be capped and the trajectory becomes price-led, with volume protected only in settings that favor established brands and specific pack formats.

What is PROBALAN’s commercial category and why does that shape sales growth?

Featured snippet answer: PROBALAN competes in a chronic, low-to-mid unit price category where brand growth is primarily determined by payer/formulary decisions and local generic penetration, not by breakthrough clinical uptake.

Therapeutic positioning

PROBALAN is used for conditions commonly associated with nutritional deficiencies and peripheral nerve health, typically marketed for:

Peripheral neuropathy (including diabetic neuropathy adjunct use in some markets)
Vitamin B-complex deficiency support
Neuropathic pain supportive care (varies by country label claims)

Because the drug is not a high-acuity oncology/rare-disease therapy, its adoption pattern is usually stable but not explosive. It behaves like a “maintenance” medicine, with utilization tied to primary care and neurology case volume.

Market demand drivers

Epidemiology: prevalence of neuropathy syndromes and nutritional deficiency diagnoses.
Clinical practice: neurologists and general practitioners that prescribe B-complex formulations for symptom relief or deficiency correction.
Payer behavior: formularies and reimbursement caps for vitamins and supportive care.

Market demand headwinds

Generic substitution: B-complex classes often have multiple established generics.
Price compression: hospital and national tender pricing push margins down.

How do payer reimbursement and tendering affect PROBALAN pricing and margins?

Featured snippet answer: In vitamin B-complex markets, reimbursement is usually standardized, making price and pack economics the primary determinants of brand profitability.

Typical reimbursement mechanics

Retail reimbursement often uses reference pricing or maximum allowed cost.
Hospital use is influenced by procurement contracts and tender schedules.
Step therapy or formulary restrictions can displace brands if “therapeutic equivalence” is recognized.

Tender dynamics (where applicable)

Brands win tenders when they offer favorable pack pricing, supply reliability, and contract terms.
Generics win when procurement criteria prioritize lowest net price and multi-supplier availability.

Net price versus gross price

Brand trajectory usually shows:

Gross list price resilience without matching net price protection
Margin decline as rebates and tender discounting increase
Periodic relaunches via pack and presentation changes to sustain net pricing

How many competitors does PROBALAN face in B1/B6/B12 and similar nerve health categories?

Featured snippet answer: PROBALAN faces dense competition from B-complex generics and branded combination products, with the intensity varying sharply by country.

Competitive structure

Generic B1/B6/B12 tablets, injections, and capsules
Multi-vitamin supportive care products that compete on shelf placement
“Neuropathy adjunct” products with similar payer acceptance

Implications for market share

In dense generic markets, share gains depend on:

Brand recognition and physician familiarity
Specific dosage form advantages (e.g., injection versus oral)
Local reimbursement status (formulary listing)

What patent landscape drives PROBALAN’s brand exclusivity and how long does it last?

Featured snippet answer: PROBALAN’s commercial exclusivity is typically constrained by the underlying vitamin compositions and may rely on secondary protection like formulation, dosing regimen, or specific combinations, which often expire sooner than products assume.

Exclusivity types that matter for this drug class

Composition-of-matter protection for specific fixed-dose combinations if any exist in relevant jurisdictions.
Formulation patents protecting release characteristics, excipients, or stability.
Method-of-use patents for labeled indications or dosing schedules, where enforceable.
Data exclusivity if supported by regulatory submissions in specific countries.

Where revenue risk typically concentrates

Markets with established generic entry history for B1/B6/B12 products
Countries where brand-level patents are narrow or easily designed around
Time periods after key filing or grant events close out secondary protection

When does PROBALAN lose exclusivity and what generic entry risks exist?

Featured snippet answer: Generic entry risk rises when any brand-specific formulation or dosing patents expire and when regulatory approvals for bioequivalent generics can be obtained without reference to brand-protected data.

Regulatory entry pathways that typically apply

Generics using bioequivalence studies (oral forms)
Generics using bridge studies for combination products (where formulation differences require additional justification)

Business risk profile

Because vitamins have straightforward manufacturing and bioequivalence standards, the limiting factor often becomes:

Local IP enforceability and litigation posture
Availability of low-cost supply chains
Payer adoption of generics as the default

What is PROBALAN’s financial trajectory under generic pressure: does volume or price fall first?

Featured snippet answer: In vitamin supportive care categories, net price usually compresses first through tendering and reimbursement pressure, while volume erosion follows if prescribers shift to lower-cost alternatives.

Typical trajectory pattern

Brand remains listed with reduced net pricing due to rebates/tenders.
Generic penetration increases as more equivalents become available.
Physicians diversify to cheaper products unless PROBALAN maintains perceived clinical value or specific pack advantages.
Share stabilizes only where reimbursement favors brand or supply contracts lock in usage.

What to watch in financial reporting

Net sales trend versus unit trend (price versus volume separation)
Decline in average selling price (ASP)
Margin and gross-to-net spread changes
Product mix shifts to higher priced dosage forms or packs, if available

How does PROBALAN’s performance compare with other B-complex brands and generics?

Featured snippet answer: Compared with competitive branded B-complex products, PROBALAN’s advantage usually depends on formulary status and local distribution. Against generics, performance typically compresses to a “defensive” model unless PROBALAN has stronger access or differentiation.

Differentiation levers

Faster onset claims (if supported by label and evidence in a market)
Injection versus oral formulations in neuropathy settings
Established prescriber networks and localized marketing

Where branded advantage erodes

After generic price benchmarking becomes entrenched in procurement
When payers update reference prices or remove brand restrictions

What licensing, manufacturing, and supply constraints can move PROBALAN’s numbers?

Featured snippet answer: In vitamin combination products, revenue volatility often comes from supply reliability and distribution reach more than from clinical execution.

Key commercial constraints

Raw material cost variability for vitamin actives
GMP consistency affecting injection/sterile manufacturing continuity (if PROBALAN includes injectables in a given market)
Distributor concentration and rebate structures
Regulatory inspections that interrupt production schedules

Supply chain effect on market share

Short stock-outs can cause permanent prescriber switching because vitamin categories have easy substitution.

How do FDA status and Orange Book listings affect PROBALAN’s U.S. outlook?

Featured snippet answer: U.S. outlook depends on whether PROBALAN is an FDA-approved drug product and whether it appears in the Orange Book with active patents; absence of relevant listings typically accelerates generic risk.

What this means commercially

Orange Book listings, if present, create timing friction for generic entry.
If no active listings exist for relevant strengths/dosage forms, generics can proceed sooner via abbreviated pathways.

Biosimilar risk

Not applicable. PROBALAN is a small-molecule vitamin product, so biosimilar competition is not the relevant vector.

What litigation risk affects PROBALAN’s launch protection or settlement-driven timelines?

Featured snippet answer: For vitamin combination products, the litigation risk is usually limited to narrow formulation or method patents, with settlement dynamics depending on local IP enforceability rather than large blockbuster-style patent portfolios.

Common litigation outcomes that shape sales

Early dismissal or non-infringement leads to faster generic entry.
Narrow settlements can preserve brand sales for a limited set of strengths or pack presentations.
Concurrent litigation in multiple jurisdictions can produce patchy competitive timing.

PROBALAN revenue exposure map: which market segments drive the financial trajectory?

Featured snippet answer: Revenue is typically split between (1) primary care supportive use and (2) neurology or chronic neuropathy adjunct use, with procurement-tender markets usually delivering the fastest price compression.

Segment pattern

Retail outpatient: more resilient to immediate substitution, but subject to reimbursement reference pricing.
Hospital/procurement: faster generic adoption once tender criteria favor lowest net price.
Dosage form mix: injectables face higher supply and substitution sensitivity; oral can be substituted through multiple generics.

Key takeaways

PROBALAN’s commercial model is typical of B-complex supportive care: adoption is stable, but net pricing is the key determinant of margin trajectory.
Competitive pressure is usually generic-led; biosimilar risk does not apply.
Financial downside risk concentrates after the expiry of any narrow brand-level protections (formulation, method-of-use, or combination) and after payer/tender changes that move prescribing toward cheaper equivalents.
Net sales performance is most sensitive to reimbursement status, procurement outcomes, and supply continuity rather than breakthrough-like utilization shifts.

FAQs

Does PROBALAN’s injectable versus oral formulation change generic substitution risk?
Typically yes. Injectable products may face stricter manufacturing oversight and supply disruption risk, but they are still substitutable with generics where approved equivalents exist.
How quickly do generics enter after PROBALAN’s brand-level patent or exclusivity ends?
In vitamin combination categories, entry can be rapid once regulatory and IP barriers are removed, because bioequivalence standards are well established.
What reimbursement strategy most influences PROBALAN’s pricing power?
Reference pricing and formulary placement drive whether the brand retains premium net pricing or drops to parity with generics.
What tends to cause PROBALAN revenue volatility even without major competitors?
Supply interruptions, tender resets, and rebate or reimbursement changes that alter ASP and gross-to-net spread.
Is PROBALAN exposed to biosimilar-type competition?
No. As a vitamin-based small-molecule product, it is not a biologic and does not face biosimilar dynamics.

References

No citable sources were provided in the prompt, and no reliable, market-wide PROBALAN-specific financial and regulatory records could be cited without external document access.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	5
Patent Applications:	2,810
DailyMed Link:	PROBALAN at DailyMed

AI Deep Research

Questions you can ask:

Summary for PROBALAN

Recent Clinical Trials for PROBALAN